Show simple item record

dc.contributor.authorKroken, Runeen_US
dc.contributor.authorLøberg, Else-Marieen_US
dc.contributor.authorDrønen, Toreen_US
dc.contributor.authorGrüner, Renateen_US
dc.contributor.authorHugdahl, Kennethen_US
dc.contributor.authorKompus, Kristiinaen_US
dc.contributor.authorSkrede, Siljeen_US
dc.contributor.authorJohnsen, Eriken_US
dc.description.abstractAntipsychotic drugs have thus far focused on dopaminergic antagonism at the D2 receptors, as counteracting the hyperdopaminergia in nigrostriatal and mesolimbic projections has been considered mandatory for the antipsychotic action of the drugs. Current drugs effectively target the positive symptoms of psychosis such as hallucinations and delusions in the majority of patients, whereas effect sizes are smaller for negative symptoms and cognitive dysfunctions. With the understanding that neurocognitive dysfunction associated with schizophrenia have a greater impact on functional outcome than the positive symptoms, the focus in pharmacotherapy for schizophrenia has shifted to the potential effect of future drugs on cognitive enhancement. A major obstacle is, however, that the biological underpinnings of cognitive dysfunction remain largely unknown. With the availability of increasingly sophisticated techniques in molecular biology and brain imaging, this situation is about to change with major advances being made in identifying the neuronal substrates underlying schizophrenia, and putative pro-cognitive drug targets may be revealed. In relation to cognitive effects, this review focuses on evidence from basic neuroscience and clinical studies, taking two separate perspectives. One perspective is the identification of previously under-recognized treatment targets for existing antipsychotic drugs, including myelination and mediators of inflammation. A second perspective is the development of new drugs or novel treatment targets for well-known drugs, which act on recently discovered treatment targets for cognitive enhancement, and which may complement the existing drugs. This might pave the way for personalized treatment regimens for patients with schizophrenia aimed at improved functional outcome. The review also aims at identifying major current constraints for pro-cognitive drug development for patients with schizophrenia.en_US
dc.rightsAttribution CC BYeng
dc.titleA critical review of pro-cognitive drug targets in psychosis: convergence on myelination and inflammationen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2014 The Authors
dc.source.journalFrontiers in Psychiatry
dc.relation.projectNorges forskningsråd: 223273
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Psychiatry, child psychiatry: 757

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY